📊 DCOY Key Takeaways
Is Decoy Therapeutics Inc. (DCOY) a Good Investment?
Decoy Therapeutics is a pre-revenue pharmaceutical company with zero sales, significant operating losses (-$2.3M), and a cash burn rate of -$3.5M annually, providing only ~2.2 years of runway at current burn rates. The company exhibits no revenue generation, worsening net income trends (-124.5% YoY), and lack of insider confidence with zero Form 4 filings in 90 days, indicating fundamental business model failure or extreme development stage risk without offsetting pipeline strength demonstrated in available metrics.
Decoy Therapeutics appears to be a pre-revenue biotech with no commercial revenue, persistent operating losses, and negative free cash flow, so the core fundamental profile remains weak. The main offset is a relatively clean balance sheet with $4.81M of cash, strong current liquidity, and no meaningful leverage, which reduces near-term solvency risk but does not solve the underlying need for revenue growth or additional financing. Overall, fundamentals suggest limited business durability unless clinical or partnership progress materially improves cash generation.
Decoy Therapeutics Inc. Key Strengths (DCOY)
- Strong cash position of $7.8M representing 93% of total assets
- Negligible debt burden with 0.00x debt-to-equity ratio eliminating refinancing risk
- Adequate liquidity with 1.84x current ratio and 1.81x quick ratio for near-term obligations
- Strong near-term liquidity with current ratio of 5.85x and quick ratio of 5.73x
- Debt-free balance sheet lowers financial risk and interest burden
- Cash of $4.81M exceeds total liabilities of $1.85M, providing some operating flexibility
DCOY Stock Risks: Decoy Therapeutics Inc. Investment Risks
- Catastrophic cash burn of -$3.5M annually with only ~2.2 years of cash runway before insolvency
- Complete absence of revenue generation with zero sales despite prior-year existence, indicating pipeline failure or pre-clinical stage
- Deteriorating profitability trend with net income declining 124.5% YoY and worsening operating losses
- Zero insider purchasing activity over 90 days suggests management has no confidence in turnaround
- Zero revenue and recurring net losses indicate an unproven business model
- Negative operating cash flow and free cash flow of $-3.69M create financing and dilution risk
- Very weak profitability metrics, including ROE of -83.4% and ROA of -58.1%, reflect poor capital efficiency
Key Metrics to Watch
- Monthly cash burn rate and projected runway extension timeline
- Revenue generation or clinical trial milestone announcements
- Capital raise announcements or dilutive financing events
- Quarterly cash burn versus cash balance to assess runway
- Any return of revenue or partnership/licensing income that improves operating leverage
Decoy Therapeutics Inc. (DCOY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Decoy Therapeutics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
DCOY Profit Margin, ROE & Profitability Analysis
DCOY vs Healthcare Sector: How Decoy Therapeutics Inc. Compares
How Decoy Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Decoy Therapeutics Inc. Stock Overvalued? DCOY Valuation Analysis 2026
Based on fundamental analysis, Decoy Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Decoy Therapeutics Inc. Balance Sheet: DCOY Debt, Cash & Liquidity
DCOY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Decoy Therapeutics Inc.'s revenue has grown significantly by 44% over the 5-year period, indicating strong business expansion. The most recent EPS of $-69.54 indicates the company is currently unprofitable.
DCOY Revenue Growth, EPS Growth & YoY Performance
DCOY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | N/A | -$5.3M | $-2.23 |
| Q3 2022 | N/A | -$1.9M | $-2.09 |
| Q2 2022 | N/A | -$1.9M | $-0.07 |
| Q1 2022 | N/A | -$1.9M | $-0.06 |
| Q3 2021 | N/A | -$1.7M | $-0.08 |
| Q2 2021 | $571.4K | -$1.8M | $-0.07 |
| Q1 2021 | $1.1M | -$1.9M | N/A |
| Q3 2020 | $874.9K | -$903.6K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Decoy Therapeutics Inc. Dividends, Buybacks & Capital Allocation
DCOY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Decoy Therapeutics Inc. (CIK: 0001615219)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DCOY
What is the AI rating for DCOY?
Decoy Therapeutics Inc. (DCOY) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DCOY's key strengths?
Claude: Strong cash position of $7.8M representing 93% of total assets. Negligible debt burden with 0.00x debt-to-equity ratio eliminating refinancing risk. ChatGPT: Strong near-term liquidity with current ratio of 5.85x and quick ratio of 5.73x. Debt-free balance sheet lowers financial risk and interest burden.
What are the risks of investing in DCOY?
Claude: Catastrophic cash burn of -$3.5M annually with only ~2.2 years of cash runway before insolvency. Complete absence of revenue generation with zero sales despite prior-year existence, indicating pipeline failure or pre-clinical stage. ChatGPT: Zero revenue and recurring net losses indicate an unproven business model. Negative operating cash flow and free cash flow of $-3.69M create financing and dilution risk.
What is DCOY's revenue and growth?
Decoy Therapeutics Inc. reported revenue of $0.0.
Does DCOY pay dividends?
Decoy Therapeutics Inc. does not currently pay dividends.
Where can I find DCOY SEC filings?
Official SEC filings for Decoy Therapeutics Inc. (CIK: 0001615219) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DCOY's EPS?
Decoy Therapeutics Inc. has a diluted EPS of $-4.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is DCOY's fundamental grade?
Based on our AI fundamental analysis in June 2026, Decoy Therapeutics Inc. has a C grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is DCOY stock overvalued or undervalued?
Valuation metrics for DCOY: ROE of -57.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is DCOY's AI grade for 2026?
Our dual AI analysis gives Decoy Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DCOY's free cash flow?
Decoy Therapeutics Inc.'s operating cash flow is $-2.9M, with capital expenditures of $577.0K.
How does DCOY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -57.4% (avg: 15%), current ratio 1.84 (avg: 2).